The role of CCR2 in prognosis of patients with endometrial cancer and tumor microenvironment remodeling

References

• Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012;120(2 Pt 1):383–397.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA. 2019;69(1):7–34.
   Google Scholar
• Njoku K, Chiasserini D, Whetton AD, et al. Proteomic biomarkers for the detection of endometrial cancer. Cancers (Basel). 2019;11(10):1572.
   PubMed Web of Science ®Google Scholar
• Matei D, Filiaci V, Randall ME, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med. 2019;380(24):2317–2326.
   PubMed Web of Science ®Google Scholar
• Itano N, Zhuo L, Kimata K. Impact of the hyaluronan-rich tumor microenvironment on cancer initiation and progression. Cancer Sci. 2008;99(9):1720–1725.
   PubMed Web of Science ®Google Scholar
• Belli C, Trapani D, Viale G, et al. Targeting the microenvironment in solid tumors. Cancer Treat Rev. 2018;65:22–32.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309–322.
   PubMed Web of Science ®Google Scholar
• Bussard KM, Mutkus L, Stumpf K, et al. Tumor-associated stromal cells as key contributors to the tumor microenvironment. BCR. 2016;18(1):84.
   PubMed Web of Science ®Google Scholar
• Sahoo SS, Zhang XD, Hondermarck H, et al. The emerging role of the microenvironment in endometrial cancer. Cancers (Basel). 2018;10(11):408.
   PubMed Web of Science ®Google Scholar
• Felix AS, Weissfeld J, Edwards R, et al. Future directions in the field of endometrial cancer research: the need to investigate the tumor microenvironment. Eur J Gynaecol Oncol. 2010;31(2):139–144.
   PubMed Web of Science ®Google Scholar
• Kamat AA, Merritt WM, Coffey D, et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res. 2007;13(24):7487–7495.
   PubMed Web of Science ®Google Scholar
• Corrado G, Laquintana V, Loria R, et al. Endometrial cancer prognosis correlates with the expression of L1CAM and miR34a biomarkers. J Exp Clin Cancer Res. 2018;CR 37(1):139.
   PubMedGoogle Scholar
• Dellinger TH, Smith DD, Ouyang C, et al. L1CAM is an independent predictor of poor survival in endometrial cancer - an analysis of the cancer genome atlas (TCGA). Gynecol Oncol. 2016;141(2):336–340.
   PubMed Web of Science ®Google Scholar
• Franca CN, Izar MCO, Hortencio MNS, et al. Monocyte subtypes and the CCR2 chemokine receptor in cardiovascular disease. Clin Sci. 2017;131(12):1215–1224.
   Web of Science ®Google Scholar
• Tan X, Hu L, Shu Z, et al. Role of CCR2 in the development of streptozotocin-treated diabetic cardiomyopathy. Diabetes. 2019;68(11):2063–2073.
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martinez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.
   PubMed Web of Science ®Google Scholar
• Otasek D, Morris JH, Boucas J, et al. Cytoscape Automation: empowering workflow-based network analysis. Genome Biol. 2019;20(1):185.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550.
   PubMed Web of Science ®Google Scholar
• Dai C, Xu P, Liu S, et al. Long noncoding RNA ZEB1-AS1 affects paclitaxel and cisplatin resistance by regulating MMP19 in epithelial ovarian cancer cells. Arch Gynecol Obstet. 2021;303(5):1271–1281
   PubMed Web of Science ®Google Scholar
• Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–W514.
   PubMed Web of Science ®Google Scholar
• Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200–4202.
   PubMed Web of Science ®Google Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.
   PubMed Web of Science ®Google Scholar
• Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr Opin Genet Dev. 2005;15(1):97–101.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–1022.
   PubMed Web of Science ®Google Scholar
• Kidd S, Spaeth E, Watson K, et al. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PloS One. 2012;7(2):e30563.
   PubMed Web of Science ®Google Scholar
• Ventriglia J, Paciolla I, Pisano C, et al. Immunotherapy in ovarian, endometrial and cervical cancer: state of the art and future perspectives. Cancer Treat Rev. 2017;59:109–116.
   PubMed Web of Science ®Google Scholar
• Arend RC, Jones BA, Martinez A, et al. Endometrial cancer: molecular markers and management of advanced stage disease. Gynecol Oncol. 2018;150(3):569–580.
   PubMed Web of Science ®Google Scholar
• Di Tucci C, Capone C, Galati G, et al. Immunotherapy in endometrial cancer: new scenarios on the horizon. J Gynecol Oncol. 2019;30(3):e46.
   PubMed Web of Science ®Google Scholar
• Mehnert JM, Panda A, Zhong H, et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest. 2016;126(6):2334–2340.
   PubMed Web of Science ®Google Scholar
• La-Beck NM, Jean GW, Huynh C, et al. Immune checkpoint inhibitors: new insights and current place in cancer therapy. Pharmacotherapy. 2015;35(10):963–976.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520.
   PubMed Web of Science ®Google Scholar
• Liao JB. Immunotherapy for gynecologic cancers. Gynecol Oncol. 2016;142(1):3–5.
   PubMed Web of Science ®Google Scholar
• Barroso-Sousa R, Ott PA. PD-1 inhibitors in endometrial cancer. Oncotarget. 2017;8(63):106169–106170.
   PubMedGoogle Scholar
• De Felice F, Marchetti C, Tombolini V, et al. Immune check-point in endometrial cancer. Int J Clin Oncol. 2019;24(8):910–916.
   PubMed Web of Science ®Google Scholar
• Oliveira MT, Kaguni LS. Functional roles of the N- and C-terminal regions of the human mitochondrial single-stranded DNA-binding protein. PloS One. 2010;5(10):e15379.
   PubMed Web of Science ®Google Scholar
• El Khoury J, Toft M, Hickman SE, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. 2007;13(4):432–438.
   PubMed Web of Science ®Google Scholar
• Deshmane SL, Kremlev S, Amini S, et al. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313–326.
   PubMed Web of Science ®Google Scholar
• Conductier G, Blondeau N, Guyon A, et al. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol. 2010;224(1–2):93–100.
   PubMed Web of Science ®Google Scholar
• Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723–737.
   PubMed Web of Science ®Google Scholar
• Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222–225.
   PubMed Web of Science ®Google Scholar
• Lim SY, Yuzhalin AE, Gordon-Weeks AN, et al. Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget. 2016;7(19):28697–28710.
   PubMedGoogle Scholar
• Fader AN, Rasool N, Vaziri SA, et al. CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes. Anticancer Res. 2010;30(12):4791–4798.
   PubMed Web of Science ®Google Scholar
• Zhang J, Lu Y, Pienta KJ. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst. 2010;102(8):522–528.
   PubMedGoogle Scholar
• Yang H, Zhang Q, Xu M, et al. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. Mol Cancer. 2020;19(1):41.
   PubMed Web of Science ®Google Scholar
• Tonouchi H, Miki C, Tanaka K, et al. Profile of monocyte chemoattractant protein-1 circulating levels in gastric cancer patients. Scand J Gastroenterol. 2002;37(7):830–833.
   PubMed Web of Science ®Google Scholar
• Hu H, Sun L, Guo C, et al. Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis. Clin Cancer Res. 2009;15(17):5485–5493.
   PubMed Web of Science ®Google Scholar
• Sahin H, Trautwein C, Wasmuth HE. Functional role of chemokines in liver disease models, Nature reviews. Gastroenterol Hepatol. 2010;7(12):682–690.
   Google Scholar
• Attar R, Agachan B, Kuran SB, et al. Association of CCL2 and CCR2 gene variants with endometrial cancer in Turkish women. vivo. 2010;24(2):243–248.
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Kiyotani K, Yew PY, et al. Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer. Oncol Rep. 2017;37(5):2603–2610.
   PubMed Web of Science ®Google Scholar